Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (ZNTL) reported promising new data for ZN-c3 and ZN-c5, highlighting their potential as best-in-class cancer therapies. The company successfully dosed the first patient in a Phase 2 trial for ZN-c3 targeting uterine serous carcinoma (USC). Additionally, Zentalis raised approximately $173 million in a public offering to support future milestones. The second quarter of 2021 saw a net loss of $55.1 million, driven by increased R&D expenses. As of June 30, 2021, Zentalis held $250.9 million in cash, which is expected to fund operations well into Q3 2023.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The event will be accessible via a live webcast on the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer, with a pipeline including candidates like ZN-c3 and ZN-c5 targeting various tumors. The company operates in New York and San Diego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of the first patient in a Phase 2 trial for ZN-c3, an oral WEE1 inhibitor, targeting recurrent uterine serous carcinoma (USC). The FDA indicated that ZN-c3 may pursue an accelerated approval pathway based on the trial's design. This Phase 2 trial aims to evaluate the drug's clinical activity, safety, and pharmacokinetics. USC has a poor prognosis, with survival rates of only 30-50%, highlighting the urgent need for effective therapies. ZN-c3 is positioned as a potentially first-in-class treatment, which could redefine USC care.
Zentera Therapeutics has successfully completed a $75 million Series B financing, led by OrbiMed Advisors Asia and Tybourne Capital Management. The funds will support the clinical development of three oncology candidates from Zentalis Pharmaceuticals (Nasdaq: ZNTL) in China, including WEE1 inhibitor ZN-c3, oral SERD ZN-c5, and BCL-2 inhibitor ZN-d5. Zentera has received four Clinical Trial Applications approved in China and aims to advance its pipeline further. The leadership team expresses confidence in becoming a leading biopharmaceutical company focused on delivering innovative cancer therapies.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has completed an underwritten public offering, raising approximately $172.9 million by selling 3,565,000 shares at $48.50 each, including 465,000 shares from underwriters' options. This funding will support Zentalis' development of oncology therapeutics targeting cancer pathways. The offering utilized an effective shelf registration statement filed with the SEC on May 4, 2021, with Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities as joint managers.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the pricing of a public offering of 3,100,000 shares of common stock at $48.50 per share, totaling approximately $150.4 million in gross proceeds. The offering, fully underwritten by Morgan Stanley and others, is set to close on July 1, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase 465,000 extra shares. The shares are offered under an effective shelf registration filed with the SEC on May 4, 2021.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced a proposed underwritten public offering of $150 million in shares of common stock, all to be sold by the company. Additionally, Zentalis may grant underwriters a 30-day option to purchase up to an additional $22.5 million in shares. The offering is being managed by Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities. This offering follows an effective shelf registration statement filed with the SEC on May 4, 2020. A preliminary prospectus supplement will soon be available on the SEC’s website.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported promising interim data from the Phase 1 trial of ZN-c3, a WEE1 inhibitor, showing increased tumor reduction and durability in heavily pretreated solid tumors. The FDA has identified a potential accelerated approval pathway for ZN-c3 in uterine serous carcinoma (USC), with multiple clinical trials underway including a registrational study. ZN-c3 also received orphan drug and rare pediatric disease designations for osteosarcoma. Concurrently, ZN-c5 shows best-in-class safety and tolerability in breast cancer treatments.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. ET. Anthony Sun, MD, Chairman and CEO, along with Melissa Epperly, CFO, will represent the company. Interested parties can access the live webcast through the Investors section of Zentalis' website, with an archived version available post-event. Zentalis focuses on developing small molecule therapeutics targeting cancer biology, including candidates like ZN-c5 and ZN-c3.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported encouraging initial results from the Phase 1 trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and multiple Exceptional Responses in heavily pre-treated cancer patients. The company has entered a clinical collaboration with GSK to explore ZN-c3 in combination with niraparib. For Q1 2021, Zentalis had cash and securities of $298.4 million, but reported a net loss of $50.4 million, up from $16.2 million in Q1 2020 due to increased R&D costs.